-
Mashup Score: 15
BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 198Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement | Verve Therapeutics - 5 month(s) ago
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results | Verve Therapeutics - 6 month(s) ago
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and Company (Lilly) Expands Through Lilly’s Acquisition of Product Rights to Verve’s PCSK9 and ANGPTL3
Source: ir.vervetx.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 5
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the lifting of the clinical hold and clearance of its
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet
Deal closed today with full exercise of green shoe Overall gross proceeds $167M, cash runway into late '26 Base offering: $125M Shoe: $18.75M Private placement to Lilly: $23M https://t.co/7MnAvDwCdT